Genicular Nerve Radiofrequency Ablation for Chronic Knee Pain After Total Knee Arthroplasty

NCT05130216 | Completed DMC

• 1 other identifier: 144989
• Study Type: observational
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

Determine if genicular nerve radiofrequency ablation (RFA) is a clinically effective intervention for patients with chronic knee pain post-total knee arthroplasty (TKA) as defined by pain.

Conditions

Total Knee Arthroplasty

Keywords

Genicular Nerve Radiofrequency Ablation; Total Knee Arthroplasty; Chronic Knee Pain

Outcome Measures

Primary Outcomes (4)

• Numeric ranking scale (NRS) pain

  NRS pain score (0 no pain - 10 severe pain)

  Prior to nerve radiofrequency ablation (RFA)

• Numeric ranking scale (NRS) pain

  NRS pain score (0 no pain - 10 severe pain)

  1-month post-genicular nerve RFA

• Numeric ranking scale (NRS) pain

  NRS pain score (0 no pain - 10 severe pain)

  3-months post-genicular nerve RFA

• Numeric ranking scale (NRS) pain

  NRS pain score (0 no pain - 10 severe pain)

  6-months post-genicular nerve RFA

Study Arms (1)

Total Knee Arthroplasty

Patients who have undergone total knee arthroplasty post one-year.

Other: Genicular Nerve Radiofrequency Ablation

Interventions

Genicular Nerve Radiofrequency Ablation OTHER

Radiofrequency Ablation (RFA)

Total Knee Arthroplasty

Eligibility Criteria

• Age: 30 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who have high pain following total knee replacement identified in clinic.

You may qualify if:

• Age 30 to 90 years
• At least one year post TKA
• Have no indications for revision TKA
• ≥4/10 knee pain for \>6 months following TKA
• ≥80% relief with diagnostic genicular nerve blocks
• Willingness to undergo fluoroscopy-guided genicular nerve RFA treatment.

You may not qualify if:

• Conditions that preclude RFA (e.g. pregnancy, pacemaker/ICD, severe cardiac/pulmonary compromise; acute illness/infection; coagulopathy or bleeding disorder; allergic reactions/contraindications to a local anesthetic.
• Inability to write, speak or read in English
• Patient refusal
• Significant psychiatric comorbidity

Sponsors & Collaborators

• University of Utah: lead

Study Sites (1)

University of Utah Orthopaedic Center

Salt Lake City, Utah, 84108, United States

Location

Study Officials

• Lucas Anderson, MD

  University of Utah Orthopaedics

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator

Study Record Dates

• First Submitted: November 10, 2021
• First Posted: November 23, 2021
• Study Start: September 22, 2021
• Primary Completion: October 1, 2025
• Study Completion: October 1, 2025
• Last Updated: January 9, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)